Return to TA88 Overview

Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block [TA88]

Measuring the use of this guidance

Recommendation: 1.1

Dual-chamber pacing is recommended for the management of symptomatic bradycardia due to sick sinus syndrome, atrioventricular block, or a combination of sick sinus syndrome and atrioventricular block, except: • in the management of atrioventricular block in patients with continuous atrial fibrillation; in this situation, single-chamber ventricular pacing is appropriate • in the management of atrioventricular block (atrioventricular block alone, or in combination with sick sinus syndrome), when patient-specific factors, such as frailty or the presence of comorbidities, influence the balance of risks and benefits in favour of single-chamber ventricular pacing. The exception about the use of dual-chamber pacing in the management of sick sinus syndrome in patients in whom, after full evaluation, there is no evidence of impaired atrioventricular conduction has been replaced by NICE technology appraisal guidance 324.

What was measured: Percentage of physiological pacing impants (dual chamber implants) as a proportion of all new impants for sick sinus syndrome
Data collection end: March 2014
87.3%
Area covered: UK
Source: National Institute for Cardiovascular Outcomes Research. National Audit of Cardiac Rhythm Management.

What was measured: Percentage of physiological pacing impants (dual chamber implants) as a proportion of all new impants for sick sinus syndrome
Data collection end: March 2016
89.5%
Area covered: UK
Source: National Institute for Cardiovascular Outcomes Research. National Audit of Cardiac Rhythm Management.

What was measured: Proportion of dual-chamber pacemaker implants for the management of sick sinus syndrome which were documented to meet NICE guidance for this indication.
Data collection end: March 2016
94%
Area covered: UK
Source: National Institute for Cardiovascular Outcomes Research. National Audit of Cardiac Rhythm Management.

What was measured: Proportion of dual-chamber pacemaker implants for the management of atrioventricular block which were documented to meet NICE guidance for this indication.
Data collection end: March 2016
92%
Area covered: UK
Source: National Institute for Cardiovascular Outcomes Research. National Audit of Cardiac Rhythm Management.



 Return to TA88 Overview